Earnings Call Summary | Revance Therapeutics(RVNC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Revance Therapeutics(RVNC.US) Q1 2024 Earnings Conference
The following is a summary of the Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript:
以下是Revance Therapeutics Inc.（RVNC）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Q1 2024 revenue of $51.9 million reported, a 13% increase due to DAXXIFY.
Net revenue of DAXXIFY aesthetic units for Q1 2024 stood at $22.1 million.
Operating expenses for Q1 were $98.8 million, higher than the $92.5 million from Q1 2023.
The company ended the quarter with over $275 million in cash, cash equivalents, and investments.
Guidance of net product revenue of at least $280 million and non-GAAP OpEx of $290 million to $310 million is reiterated.
2024年第一季度報告的收入爲5190萬美元，增長了13％，這要歸因於DAXXIFY。
2024年第一季度，DAXXIFY美容部門的淨收入爲2210萬美元。
第一季度的運營支出爲9,880萬美元，高於2023年第一季度的9,250萬美元。
該公司在本季度末擁有超過2.75億美元的現金、現金等價物和投資。
重申了淨產品收入至少爲2.8億美元，非公認會計准則運營支出爲2.9億美元至3.1億美元的指導方針。
Business Progress:
業務進展：
Unit sales of DAXXIFY aesthetic units saw a 105% YoY growth and market share increased to 3.7% in Q1 2024.
The company has entered the $2.7 billion US therapeutic neurotoxin market and expects it to grow 8% annually over the next five years.
Revance Therapeutics plans to reach positive adjusted EBITDA in 2025 with at least 32% top-line growth in 2024.
Efficiency initiatives have resulted in a decrease in non-GAAP OpEx from $91.7 million in Q4 to $73.6 million in Q1 2024.
Revance Therapeutics plans to roll out portfolio programs to incentivize further adoption of their products and plans for a larger account base by the end of the year.
The company plans to focus on digital and social marketing and has raised an additional $100 million for corporate use.
2024年第一季度，DAXXIFY美容單位的單位銷售額同比增長105％，市場份額增加到3.7％。
該公司已進入27億美元的美國治療性神經毒素市場，預計未來五年該市場每年將增長8％。
Revance Therapeutics計劃在2025年實現調整後的息稅折舊攤銷前利潤爲正，到2024年收入增長至少32％。
效率舉措導致非公認會計准則運營支出從第四季度的9,170萬美元下降至2024年第一季度的7,360萬美元。
Revance Therapeutics計劃推出投資組合計劃，以激勵其產品的進一步採用，並計劃在年底之前擴大客戶群。
該公司計劃專注於數字和社交營銷，並已額外籌集1億美元供企業使用。
More details: Revance Therapeutics IR
更多詳情： Revance 治療公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。